CN113057957A - Use of Gedunin and its derivatives in the preparation of antioxidant drugs and/or cosmetics and drugs for the treatment of rheumatoid arthritis - Google Patents
Use of Gedunin and its derivatives in the preparation of antioxidant drugs and/or cosmetics and drugs for the treatment of rheumatoid arthritis Download PDFInfo
- Publication number
- CN113057957A CN113057957A CN202110343576.8A CN202110343576A CN113057957A CN 113057957 A CN113057957 A CN 113057957A CN 202110343576 A CN202110343576 A CN 202110343576A CN 113057957 A CN113057957 A CN 113057957A
- Authority
- CN
- China
- Prior art keywords
- gdn
- rheumatoid arthritis
- antioxidant
- cosmetic
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 42
- 239000002537 cosmetic Substances 0.000 title claims abstract description 32
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 30
- 229940079593 drug Drugs 0.000 title claims abstract description 28
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- YJXDGWUNRYLINJ-BHAPSIHVSA-N gedunin Chemical compound C=1([C@H]2[C@]3(C)CC[C@@H]4[C@@]5(C)C=CC(=O)C(C)(C)[C@@H]5C[C@H]([C@]4([C@]33O[C@@H]3C(=O)O2)C)OC(=O)C)C=COC=1 YJXDGWUNRYLINJ-BHAPSIHVSA-N 0.000 title abstract description 11
- HPXDQBYDTJMQHA-UHFFFAOYSA-N Gedunin Natural products CC1CC2C3(C)C=CC(=O)C(C)(C)C3CC(OC(=O)C)C2(C)C45OC4C(=O)OC(C15)c6cocc6 HPXDQBYDTJMQHA-UHFFFAOYSA-N 0.000 title abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 7
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 239000012453 solvate Substances 0.000 claims abstract description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 5
- 108010018924 Heme Oxygenase-1 Proteins 0.000 claims description 8
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 101710088194 Dehydrogenase Proteins 0.000 claims description 2
- 102000002737 Heme Oxygenase-1 Human genes 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 230000003020 moisturizing effect Effects 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 230000004663 cell proliferation Effects 0.000 abstract description 8
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 24
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 19
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 19
- 235000006708 antioxidants Nutrition 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 12
- 206010003246 arthritis Diseases 0.000 description 11
- 229920002961 polybutylene succinate Polymers 0.000 description 10
- 239000004631 polybutylene succinate Substances 0.000 description 10
- 210000000548 hind-foot Anatomy 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- HCEYJYMNIQHPPK-UHFFFAOYSA-N 7-Deacetoxy-7-hydroxy-gedunin Natural products CC12C=CC(=O)C(C)(C)C1CC(O)C(C13OC1C(=O)O1)(C)C2CCC3(C)C1C=1C=COC=1 HCEYJYMNIQHPPK-UHFFFAOYSA-N 0.000 description 6
- HCEYJYMNIQHPPK-DXTZDJJUSA-N 7-deacetylgedunin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)[C@H](O)C[C@H]2C(C(C=C[C@@]24C)=O)(C)C)C=COC=1 HCEYJYMNIQHPPK-DXTZDJJUSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010051728 Bone erosion Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100028006 Heme oxygenase 1 Human genes 0.000 description 4
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 description 4
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 102000000503 Collagen Type II Human genes 0.000 description 3
- 108010041390 Collagen Type II Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000009386 Experimental Arthritis Diseases 0.000 description 3
- 101150116862 KEAP1 gene Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical group C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000010603 microCT Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000012223 nuclear import Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- -1 polybutylene succinate Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000425037 Toona sinensis Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000011764 rheumatoid arthritis animal model Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000001612 separation test Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides application of gedunin and derivatives thereof in preparing antioxidant drugs and/or cosmetics and drugs for treating rheumatoid arthritis, belonging to the field of medicines. In particular to a formula I instituteThe use of the compound shown in the specification, or a salt, a stereoisomer, a solvate or a hydrate thereof in the preparation of an antioxidant drug and/or cosmetic and/or a drug for treating rheumatoid arthritis, wherein R is1～R6Are respectively and independently selected from hydrogen and C1～C6Alkyl, -C (O) R7；R7Is selected from C1～C6An alkyl group. The research of the invention finds that GDN and the derivative 7-d-GDN thereof can obviously inhibit RASFs cell proliferation, have the effect of treating rheumatoid arthritis, and can be used for preparing the medicine for treating rheumatoid arthritis; meanwhile, GDN and the derivative 7-d-GDN thereof have antioxidation, can be used for preparing antioxidant medicines, and can also be used for preparing antioxidant and anti-aging cosmetics. The new application of the GDN and the derivative 7-d-GDN thereof has better application prospect.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to application of kuduoning and derivatives thereof in preparation of anti-oxidation medicines and/or cosmetics and medicines for treating rheumatoid arthritis.
Background
Rheumatoid Arthritis (RA) is a chronic systemic disease with an unknown etiology, mainly inflammatory synovitis, and belongs to an autoimmune disease. It is characterized by multiple joints, symmetry and invasive arthritis of small joints of hands and feet, and joint deformity and function loss caused by the fact that the external organs of joints are affected by serum rheumatoid factor positivity. The pathogenesis of the disease can be related to heredity, infection and sex hormone. Rheumatoid arthritis can be seen at any age, with 80% of cases occurring at 35-50 years of age, and about 3 times as many female patients as male patients. At present, the rheumatoid arthritis is mostly treated by medicaments, which mainly comprise non-steroidal anti-inflammatory drugs (NSAIDs), antirheumatic drugs (DMARDs), glucocorticoids and biological antibody medicaments. However, these drugs have serious side effects or damage organs, and thus, there is an urgent need to find new therapeutic methods.
Antioxidation refers to the abbreviation of antioxidant free radical, Anti-Oxidant. The human body continuously generates free radicals in the human body due to continuous contact with the outside, including respiration (oxidation reaction), external pollution, radiation irradiation and other factors. Scientific studies have shown that cancer, aging or other diseases are mostly associated with the production of excess free radicals. The antioxidant medicine can reduce damage of oxygen free radicals to blood vessel wall, thereby playing a role in resisting arteriosclerosis. The cosmetics with the antioxidation function can also play a role in beautifying and maintaining, so the research on the antioxidation medicaments or the cosmetics has important significance.
Gedunnin (GDN) and 7-deacetyl Gedunnin (7-d-GDN) are active ingredients of plant Cedrela sinensis, and the molecular formula of GDN is C28H34O7Molecular weight of 482.57, CAS number of 2753-30-2; the molecular formula of 7-d-GDN is C26H34O6Molecular weight of 442.54, CAS number 10314-91-7; their chemical structures are as follows:
GDN and 7-d-GDN have various biological activities, such as antibacterial, antiallergic, and analgesic effects. However, GDN and 7-d-GDN have not been found to have the effects of treating rheumatoid arthritis and resisting oxidation.
Disclosure of Invention
The invention aims to provide application of gedunin and derivatives thereof in preparing antioxidant drugs and/or cosmetics and drugs for treating rheumatoid arthritis.
The invention provides an application of a compound shown as a formula I, or a salt, a stereoisomer, a solvate or a hydrate thereof in preparing an antioxidant drug and/or a cosmetic and/or a drug for treating rheumatoid arthritis:
wherein R is1～R6Are respectively and independently selected from hydrogen and C1～C6Alkyl, -C (O) R7；
R7Is selected from C1～C6An alkyl group.
Further, the compound is represented by formula II:
wherein R is1～R6Are respectively and independently selected from hydrogen and C1～C6Alkyl, -C (O) R7；
R7Is selected from C1～C6An alkyl group.
Further, the compound is represented by formula III:
wherein R is1Selected from hydrogen, C1～C6Alkyl, -C (O) R7；
R7Is selected from C1～C6An alkyl group.
Further, the compound is one of the following compounds:
further, the rheumatoid arthritis is autoimmune disease rheumatoid arthritis.
Further, the antioxidant drugs and/or cosmetics are drugs and/or cosmetics for inhibiting Reactive Oxygen Species (ROS).
Further, the antioxidant medicine and/or cosmetic is medicine and/or cosmetic for up-regulating antioxidant heme oxygenase-1, NAD (P) H dehydrogenase quinone;
preferably, the antioxidant drugs and/or cosmetics are anti-aging drugs and/or cosmetics.
Furthermore, the antioxidant medicine and/or cosmetic is a pharmaceutical preparation or cosmetic prepared by taking a compound shown in formula I, or a salt, a stereoisomer, a solvate or a hydrate thereof as an active ingredient and adding auxiliary materials acceptable in the pharmaceutical or cosmetic field;
the medicine for treating rheumatoid arthritis is a medicinal preparation which is prepared by taking a compound shown in a formula I, or a salt, a stereoisomer, a solvate or a hydrate thereof as an active ingredient and adding pharmaceutically acceptable auxiliary materials.
Further, the pharmaceutical preparation is tablets, granules, capsules, dripping pills, injections, powder injections or aerosols; the cosmetic is a toner, a lotion, a moisturizing cream or a sun-screening cream, a cream or a spray.
Further, in the pharmaceutical preparation, the content of GDN and 7-d-GDN per unit preparation is 0.1-99 wt%; preferably 0.5 to 50 wt%.
Unless otherwise indicated, percentages and parts referred to herein are by weight.
The research of the invention finds that GDN and the derivative 7-d-GDN thereof can obviously inhibit RASFs cell proliferation, have the effect of treating rheumatoid arthritis, and can be used for preparing the medicine for treating rheumatoid arthritis; meanwhile, GDN and the derivative 7-d-GDN thereof have antioxidation, can be used for preparing antioxidant medicines, and can also be used for preparing antioxidant and anti-aging cosmetics. The new application of the GDN and the derivative 7-d-GDN thereof has better application prospect.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Drawings
FIG. 1 shows the results of inhibition of RASFs cell proliferation by gedunin and 7-deacetylgedunin: a is the influence of gedunin on the cell viability of RASFs; b is the effect of gedunin on cell proliferation of RASFs; c is the effect of 7-deacetyl gedunin on cell viability of RASFs; d is the effect of 7-deacetylgedunin on cell proliferation of RASFs.
Figure 2 is a graph of the therapeutic effect of GDN on rheumatoid arthritis mice: a is the change in thickness of the hind paw of each group of rheumatoid arthritis mice; b is the arthritis score of each group of rheumatoid arthritis mice; and C is the body weight of each group of rheumatoid arthritis mice.
FIG. 3 is a micro-CT image of various groups of rheumatoid arthritis mice and statistics of bone erosion and bone volume.
FIG. 4 is a graph of the effect of GDN and 7-d-GDN on ROS expression.
FIG. 5 shows the results of GDN and 7-d-GDN inducing translocation of Nrf2 into the nucleus in RAW264.7 cells: a is the influence of GDN on the HO-1 gene downstream of Nrf 2; b is the effect of GDN on NQO1 of the downstream gene of Nrf 2; c and D are the influence of GDN on the expression of each protein in RAW264.7 cells; the effect of E is 7-d-GDN on NQO1 of a gene downstream of Nrf 2; f is the influence of 7-d-GDN on the downstream gene HO-1 of Nrf 2; g and H are the influence of 7-d-GDN on the expression of each protein in RAW264.7 cells; i is the effect of GDN on nuclear entry of Nrf 2; j is the effect of 7-d-GDN on nuclear import of Nrf 2.
FIG. 6 shows the results of GDN and 7-d-GDN inducing translocation of Nrf2 into the nucleus in RASFs cells: a is GDN for inducing Nrf2 to enter nucleus in RASFs; b is a cytoplasm and nucleus separation test which further proves that GDN induces Nrf2 to enter nucleus in RASFs; c is 7-d-GDN induces Nrf2 to enter the nucleus in RASFs; d is the statistical data of the graph C.
Detailed Description
The raw materials and equipment used in the embodiment of the present invention are known products and obtained by purchasing commercially available products.
Gedunin (GDN) and 7-deacetyl Gedunin (7-d-GDN) used in the embodiments of the present invention were purchased from sigma.
EXAMPLE 1 Effect of Kualtunin and 7-deacetyl Kualtunin on the treatment of rheumatoid arthritis experiment one
The formation of synovial fibroblasts (RASFs) plays an important role in the pathogenesis of Rheumatoid Arthritis (RA), and is a key factor in the occurrence and development of the RA. This experiment investigated the inhibitory effect of Gedunin (GDN) and 7-deacetylgedunin (7-d-GDN) on cells of RASFs, demonstrating the therapeutic effect of GDN and 7-d-GDN on rheumatoid arthritis.
(1) MTT assay
RASFs cells (5X 10)3Per well) were seeded in 96-well plates for 24h, then treated with different concentrations of GDN (0, 1, 5, 10, 25, 50, 100, 150 μ M) and 7-d-GDN (0, 1, 5, 10, 25, 50, 100, 150 μ M) for 24h, 48h and 72h, respectively. After treatment, the plates were reacted with MTT (5mg/mL) for 4h, the supernatant was carefully removed, DMSO was added to a 96-well plate, and the purple precipitate was dissolved by shaking for 15 min. Cell viability was measured at 490nm using an OD plate reader per well. The formula for calculating cell viability is as follows: cell viability (%) ═ OAAfter treatment/OAControl。
(2) Cell proliferation assay (BRDU)
RASFs (5x 10)3Per well) were seeded in 96-well plates for 24h, and then treated with different concentrations of GDN and 7-d-GDN (at 0, 1, 5, 10, 25, 50, 75, 100, 150. mu.M, respectively) for 24h, 48h, 72h, respectively, following the protocol of the cell proliferation assay. RASFs add BRDU (1x) label 16 hours before experimental detection and cell collection, then remove the label liquid, dry the labeled cells, add 200 μ l/well FixDenat, incubate for 30min at 15 ℃ -25 ℃. Taking outAnd adding 100 mu l/hole anti-BRDU-POD working solution into the FixDenat solution, and incubating for 90min at 15-25 ℃. The wells were washed 3 times with (300. mu.l/well) wash solution. Adding substrate solution (100 μ l/well), incubating at 15-25 deg.C for 5-30min, and adding 1M H per well until the color development amount is enough for photometric detection2SO4Incubations were performed (25. mu.l/well). The excitation was carried out for 1 minute on a 300-turn exciter and the absorbance was finally measured at 450/690 nm.
(3) Test results
The results of cell viability and cell proliferation are shown in fig. 1, and the results of the experiment show that: kuduning (GDN) and 7-deacetyl Kuduning (7-d-GDN) have significant inhibitory effect on cell proliferation of RASFs. The inhibitory effect of GDN and 7-d-GDN on RASFs cells indicates that they have therapeutic effect on rheumatoid arthritis.
Second, therapeutic action on rheumatoid arthritis mouse
(1) Therapeutic effect on Collagen (CIA) -induced DBA mouse arthritis
The DBA mouse Collagen Induced Arthritis (CIA) model is a classic rheumatoid arthritis animal model, is widely applied to evaluation of possible etiology and pathology of RA, and is also used for evaluation of a new treatment method of RA. The invention utilizes the model to evaluate the treatment effect of the kuduoning on the rheumatoid arthritis.
Placing equal volume of Freund incomplete adjuvant (CFA) and bovine type II collagen in a mortar, and uniformly grinding until the color changes from gray to white (grinding time is generally not less than 30 min). Throughout the emulsification process, the collagen should be kept in ice. To obtain the ideal arthritis model, DBA mice were immunized 2 times in total. Briefly, the tail and proximal tail of each DBA mouse were first sterilized by 75% ethanol washing and first immunized by injecting subcutaneously bovine type ii collagen (100 μ l) emulsified in CFA with a glass syringe. After 21 days, mice were injected with bovine type II collagen (100. mu.l) emulsified in CFA for secondary immunization to boost induction.
8 week old mice were randomized into 5 groups: control group (Control): normal mice were fed on a routine feeding standard throughout the experiment; model group (Model): injecting the preparation solution into the abdominal cavity of the molded mouse every day; ③ methotrexate group (MTX): the gavage methotrexate is used for the mice after the model building, and the dosage is 10mg/kg/d and 200 mul/body/3 d; (iv) GDN group (2.5 mg/kg/d dose group and 5mg/kg/d dose group, respectively): the mice after molding were injected intraperitoneally with different doses of GDN, 200. mu.l/body, respectively, at the time of the second immunization, and were continuously injected for 20 days until the end of the experiment.
Severity of arthritis was recorded every two days, including arthritis score, double hind paw thickness and body weight; and observing the bone erosion and bone volume of the joints of the mice after treatment through micro-CT. The arthritis score was determined by the severity of arthritis, and was assessed from 0 to 4 for edema and erythema in the tissues surrounding each affected hindpaw joint. 0-no inflammation, 1-mild, 2-moderate, 3-severe, and 4-disability. Scoring was performed by two independent observers without knowledge of the experimental group. The hind paw thickness was measured with a vernier caliper and expressed as the average thickness of the two hind paws of the mouse. The hind paw thickness was measured on the day of the second immunization and the change in hind paw thickness was calculated by subtracting the hind paw thickness measured on the day of the second immunization from the hind paw thickness measured on the day of the second immunization, with the same change in body weight. The measurement started after the second immunization and continued for about 20 days until the end of the experiment.
(2) Test results
The experimental results are shown in FIGS. 2 to 3. As can be seen from FIGS. 2 to 3: compared with a control group, the arthritis of the mice after the model building is very serious, the arthritis score is high, the thickness of double hind paws is increased, the weight is reduced, the bone erosion is serious, and the bone volume is reduced. Whereas, following treatment with GDN, mice had significantly reduced arthritis scores, reduced double hind paw thickness, weight gain and significantly reduced bone erosion. Meanwhile, researches find that the toxic and side effects of GDN are small. The results show that GDN can improve the relevant symptoms of rheumatoid arthritis model mice, is used for treating rheumatoid arthritis, and has small toxic and side effects.
Example 2 antioxidant action of Kuduling and 7-deacetyl Kuduling
(1) ROS detection
Treatment of R with GDN (1, 5, 10, 25, 50. mu.M) and 7-d-GDN (1, 5, 10, 25, 50. mu.M), respectivelyASFs cells (2.5X 10)5Hole) 48h and 72 h. Then using PBS washing 1 times, trypsin collection RASFs, PBS washing, again containing DCFH-DA (5 u M) PBS staining for 30 minutes, DCFH-DA stained cells using 1500rpm centrifugation, using FACScan flow cytometry analysis of total ROS content.
(2) Antioxidant detection of gedunin and 7-deacetylgedunin
(ii) immune cell fluorescence analysis
To verify whether compounds GDN and 7-d-GDN induced Nrf2 translocation into the nucleus, immunocytochemistry experiments for Nrf2 translocation into the nucleus were performed in RASFs cells and RAW264.7 cells using GDN and 7-d-GDN at different concentrations, respectively. RASFs cells (1X 10)5/well) were inoculated in 6-well plates, incubated overnight, and then treated with different concentrations of GDN and 7-d-GDN (1, 5, 10, 25, 50 μ M) for 24 h. RAW264.7 cells (1X 10)5/well) were inoculated in 6-well plates, incubated overnight, and then treated with different concentrations of GDN and 7-d-GDN (1, 5, 10, 25 μ M) for 24 h. Rinsed three times with cold polybutylene succinate (PBS). PBS was completely removed, fixed with 4% soluble Polytetrafluoroethylene (PFA) for 15min, rinsed 3 times with cold PBS, incubated with 0.1% Triton x-100 for 5min, and stained with DAPI for 30 min. Cell hatching fluid was incubated with Nrf2 antibody overnight at 4 ℃ and then incubated with secondary antibody for 2h at room temperature. After the cover was dried, the cover containing the cells was mounted on a glass slide and photographed with a fluorescence microscope.
② detection of proteins
To investigate the level of HO-1, Keap1 and Nrf2 regulated by GDN, 7-d-GDN in RASFs cells, RASFs cells (2.5X 10)5Perwell) were placed in 6-well plates and treated with different concentrations of GDN, 7-d-GDN (1, 5, 10, 25, 50. mu.M) for 24 h. To investigate the GDN-regulated levels of HO-1, Keap1 and Nrf2 in RAW264.7 cells, RAW264.7(2.5X 10)5Perwell) were placed in 6-well plates and treated with different concentrations of GDN, 7-d-GDN (1, 5, 10, 25, 50. mu.M) for 24 h. After treatment with different concentrations of GDN, 7-d-GDN, cells were harvested and lysed on ice with 1 XPAP containing 1 XPA protease inhibitor. Total protein of the supernatant was collected after centrifugation at 12000g/min for 15min, and the total protein concentration was determined using the Bio-Rad concentrated protein kit. Briefly, 2. mu.l of the protein from the different samples were added to 800. mu.l dd water, followed by 200. mu.l of Bio-Rad protein detection reagent, vortexed for 30s, incubated for 5min, and absorbance measured at 595nm using a plate reader. Mixing protein and 5 Xprotein sample buffer solution at a volume ratio of 4:1, denaturing at 100 deg.C for 10min, and storing at-80 deg.C for a long period (1 year). Proteins were separated by gel electrophoresis, transferred to Nitrocellulose (NC) membranes, blocked with 5% free skim milk in PBS buffer containing 0.1% Tween 20, and recognized by specific antibodies.
③ Gene detection
RAW264.7 cells (1X 10)6Per well) were inoculated into 6-well plates, preincubated with different concentrations of GDN, 7-d-GDN (1, 5, 10, 25. mu.M) for 1h, and then incubated with LPS (100ng/ml) for 24 h. Wash 2 times with cold PBS and aspirate PBS. Total RNA from cells was extracted with 1 ml/well Trizol, lysed at room temperature for 5min, and transferred to 1.5ml tubes. Add 200. mu.l chloroform, incubate for 10min, centrifuge at 12000g/min for 15min at 4 ℃. The upper layer was collected, incubated with an equal volume of 100% isopropanol for 10min, and centrifuged at 12000g/min at 4 ℃ for 10 min. The supernatant was removed and the pellet was total RNA, washed 2 times with 75% ethanol. Drying, and dissolving with RNase-free water. Total RNA concentration was then calculated by uv spectrophotometry (Nanodrop, Thermo) at λ -260/280 nm. Then the expression level of HO-1 and NQO1 mRNA is detected by RT-PCR.
(3) Test results
As can be seen from fig. 4: GDN and 7-d-GDN can inhibit ROS expression, and have antioxidant effect. As can be seen from fig. 5 and 6: GDN and 7-d-GDN can inhibit Keap1 expression in RAW264.7 cells, promote Nrf2 to enter nucleus and up-regulate HO-1 and NQO1 expression of downstream genes of Nrf 2; it also facilitates nuclear import of Nrf2 in RASFs.
The above test results show that GDN and 7-d-GDN have antioxidant effects.
In conclusion, the research of the invention finds that GDN and the derivative 7-d-GDN thereof can obviously inhibit RASFs cell proliferation, have the effect of treating rheumatoid arthritis, and can be used for preparing the medicine for treating rheumatoid arthritis; meanwhile, GDN and the derivative 7-d-GDN thereof have antioxidation, can be used for preparing antioxidant medicines, and can also be used for preparing antioxidant and anti-aging cosmetics. The new application of the GDN and the derivative 7-d-GDN thereof has better application prospect.
Claims (10)
1. The application of the compound shown in the formula I, or a salt, a stereoisomer, a solvate or a hydrate thereof in preparing an antioxidant drug and/or cosmetic and/or a drug for treating rheumatoid arthritis:
wherein R is1～R6Are respectively and independently selected from hydrogen and C1～C6Alkyl, -C (O) R7；
R7Is selected from C1～C6An alkyl group.
2. Use according to claim 1, characterized in that: the compound is represented by formula II:
wherein R is1～R6Are respectively and independently selected from hydrogen and C1～C6Alkyl, -C (O) R7；
R7Is selected from C1～C6An alkyl group.
3. Use according to claim 2, characterized in that: the compound is shown as formula III:
wherein R is1Selected from hydrogen, C1～C6Alkyl, -C (O) R7；
R7Is selected from C1～C6An alkyl group.
4. Use according to any one of claims 1 to 3, characterized in that: the compound is one of the following compounds:
5. use according to claim 1, characterized in that: the rheumatoid arthritis is autoimmune disease rheumatoid arthritis.
6. Use according to claim 1, characterized in that: the antioxidant medicine and/or cosmetic is medicine and/or cosmetic for inhibiting Reactive Oxygen Species (ROS).
7. Use according to claim 1, characterized in that: the antioxidant medicine and/or cosmetic is medicine and/or cosmetic for up-regulating antioxidant enzyme heme oxygenase-1, NAD (P) H dehydrogenase quinone;
preferably, the antioxidant drugs and/or cosmetics are anti-aging drugs and/or cosmetics.
8. Use according to claim 1, characterized in that: the antioxidant medicine and/or cosmetic is a pharmaceutical preparation or cosmetic prepared by taking a compound shown in a formula I, or a salt, a stereoisomer, a solvate or a hydrate thereof as an active ingredient and adding pharmaceutically or cosmetically acceptable auxiliary materials;
the medicine for treating rheumatoid arthritis is a medicinal preparation which is prepared by taking a compound shown in a formula I, or a salt, a stereoisomer, a solvate or a hydrate thereof as an active ingredient and adding pharmaceutically acceptable auxiliary materials.
9. Use according to claim 8, characterized in that: the pharmaceutical preparation is tablet, granule, capsule, dripping pill, injection, powder for injection or aerosol; the cosmetic is a toner, a lotion, a moisturizing cream or a sun-screening cream, a cream or a spray.
10. Use according to claim 8 or 9, characterized in that: in the pharmaceutical preparation, the content of GDN and 7-d-GDN in each unit preparation is 0.1-99 wt%; preferably 0.5 to 50 wt%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110343576.8A CN113057957A (en) | 2021-03-30 | 2021-03-30 | Use of Gedunin and its derivatives in the preparation of antioxidant drugs and/or cosmetics and drugs for the treatment of rheumatoid arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110343576.8A CN113057957A (en) | 2021-03-30 | 2021-03-30 | Use of Gedunin and its derivatives in the preparation of antioxidant drugs and/or cosmetics and drugs for the treatment of rheumatoid arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113057957A true CN113057957A (en) | 2021-07-02 |
Family
ID=76564886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110343576.8A Pending CN113057957A (en) | 2021-03-30 | 2021-03-30 | Use of Gedunin and its derivatives in the preparation of antioxidant drugs and/or cosmetics and drugs for the treatment of rheumatoid arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113057957A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1607956A (en) * | 2001-12-28 | 2005-04-20 | 雅芳产品公司 | Topical cosmetic composition having a natural plant active ingredient and method of using same |
| CN1969841A (en) * | 2005-11-24 | 2007-05-30 | 牛蓉 | Herbal extract for treating rheumatoid arthritis |
| CN101018558A (en) * | 2004-07-21 | 2007-08-15 | 奥斯瓦道·克鲁兹基金会 | Pharmaceutical compositions from carapa guianensis |
| US20140050694A1 (en) * | 2012-08-20 | 2014-02-20 | Wisconsin Alumni Research Foundation | Method of Treating Transplant Rejection and Autoimmune Diseases |
| US20180251489A1 (en) * | 2015-08-28 | 2018-09-06 | Cornell University Cornell Center for Technology Enterprise & Commercialization (CCTEC) | Malt1 inhibitors and uses thereof |
| CN109803664A (en) * | 2016-06-15 | 2019-05-24 | 尚特·德扎尔基西安 | Reagents, compositions and methods for improving viability and function of cells, tissues and organs |
| CN110167558A (en) * | 2016-12-21 | 2019-08-23 | 阿泽克制药公司 | Triazinetrione derivative and its purposes as neurenergen-3 receptor and the regulator of receptor tyrosine kinase |
-
2021
- 2021-03-30 CN CN202110343576.8A patent/CN113057957A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1607956A (en) * | 2001-12-28 | 2005-04-20 | 雅芳产品公司 | Topical cosmetic composition having a natural plant active ingredient and method of using same |
| CN101018558A (en) * | 2004-07-21 | 2007-08-15 | 奥斯瓦道·克鲁兹基金会 | Pharmaceutical compositions from carapa guianensis |
| CN1969841A (en) * | 2005-11-24 | 2007-05-30 | 牛蓉 | Herbal extract for treating rheumatoid arthritis |
| US20140050694A1 (en) * | 2012-08-20 | 2014-02-20 | Wisconsin Alumni Research Foundation | Method of Treating Transplant Rejection and Autoimmune Diseases |
| US20180251489A1 (en) * | 2015-08-28 | 2018-09-06 | Cornell University Cornell Center for Technology Enterprise & Commercialization (CCTEC) | Malt1 inhibitors and uses thereof |
| CN109803664A (en) * | 2016-06-15 | 2019-05-24 | 尚特·德扎尔基西安 | Reagents, compositions and methods for improving viability and function of cells, tissues and organs |
| CN110167558A (en) * | 2016-12-21 | 2019-08-23 | 阿泽克制药公司 | Triazinetrione derivative and its purposes as neurenergen-3 receptor and the regulator of receptor tyrosine kinase |
Non-Patent Citations (6)
| Title |
|---|
| CHEN J. ET AL: "7-deacetylgedunin suppresses inflammatory responses through activation of Keap1/Nrf2/HO-1 signaling", 《ONCOTARGET》 * |
| CONTE F. ET AL: "Effect of Gedunin on Acute Articular Inflammation and Hypernociception in Mice", 《MOLECULES》 * |
| MAZUMDAR S. ET AL: "Functional relevance of Gedunin as a bona fide ligand of NADPH oxidase 5 and ROS scavenger: An in silico and in vitro assessment in a hyperglycemic RBC model", 《BIOCHEMISTRY AND BIOPHYSICS REPORTS》 * |
| 张峰 等: "香椿属中三萜类化学成分及生物活性研究进展", 《现代生物医学进展》 * |
| 李思明: "《FGF21蛋白抗类风湿性关节炎研究》", 30 June 2017, 科学技术文献出版社 * |
| 谷建梅 主编: "《化妆品安全知识读本》", 30 April 2017, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9775822B2 (en) | Chlorogenic acid composition | |
| CN101862374B (en) | Lotus plumule and new application of extractive thereof | |
| TW200816982A (en) | Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment | |
| US20100292178A1 (en) | Method of treating non-insulin dependent diabetes mellitus and related complications | |
| Musumeci et al. | Iron excretion in iron dextran-overloaded mice | |
| US9913867B2 (en) | Composition comprising extract of mixture of Undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis | |
| El Habbani et al. | In vitro mass reduction of calcium oxalate urinary calculi by some medicinal plants | |
| Wu et al. | Schisandra chinensis polysaccharide protects against cyclosporin A-induced liver injury by promoting hepatocyte proliferation | |
| Sun et al. | Shouhui Tongbian Capsules induce regression of inflammation to improve intestinal barrier in mice with constipation by targeted binding to Prkaa1: With no obvious toxicity | |
| EP2762137A1 (en) | Use of myricetin or derivatives thereof as a cathepsin k inhibitor | |
| EP1859834B1 (en) | Anti-inflammatory agent | |
| CN108697723B (en) | Beneficial effects of ghost needles on building muscle and reducing fat | |
| CN113057957A (en) | Use of Gedunin and its derivatives in the preparation of antioxidant drugs and/or cosmetics and drugs for the treatment of rheumatoid arthritis | |
| CN110876741B (en) | GBE1 inhibitor frataxin and application of pharmaceutical composition thereof in preparation of drugs for treating lung adenocarcinoma | |
| Lin et al. | Fufang Zhenzhu Tiaozhi (FTZ) capsule ameliorates diabetic kidney disease in mice via inhibiting the SGLT2/glycolysis pathway | |
| Ding et al. | Effects and mechanisms of theabrownin from black tea in improving hyperuricemia: Evidence from animal study and clinical trial | |
| KR102199884B1 (en) | Composition for controlling sebum containing a substance related to regulation of ABH antigen expression | |
| CN115337351A (en) | Traditional Chinese medicine compound essential oil | |
| CN114470150A (en) | Application of chicken-derived small molecular peptide in preparation of product for preventing and improving liver injury and secondary symptoms of liver injury and product | |
| CN111388460A (en) | Antiaging Uses of Hematoxylin A | |
| KR101312025B1 (en) | Preparation method of extract of Picrasma quassioides and use of the extracts | |
| CN113476432B (en) | Application of J147 in preparing medicine/cosmetic for treating and/or preventing pigment-increment diseases | |
| CN110917186A (en) | Application of icaritin in preparation of medicine for treating bronchial asthma | |
| WO2016060298A1 (en) | Composition containing material for regulating expression of abh antigens | |
| Al Fahad et al. | Antidiarrheal Activity of the Ethanolic Extract of Operculina turpethum Stem and in silico Molecular Docking and ADMET Analysis of Its Isolated Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210702 |
|
| RJ01 | Rejection of invention patent application after publication |